Raltitrexed (Tomudex™)

Bibliography

• BORING CC, SQUIRES TS, TONG T, MONTGOMERY S: Cancer statistics. CA Cancer J. Clin. (1994) 44:7–26.
   PubMed Web of Science ®Google Scholar
• JENSEN OM, ESTEVE J, MOLLER H, RENARD H: Cancer in the European Community and its member states. Eur. J. Cancer (1990) 26:1167–1256.
   PubMed Web of Science ®Google Scholar
• SOBRERO A: Introduction. Anticancer Drugs (1997) 8\(Suppl. 2):S1–S3.
   Google Scholar
• BLEIBERG H: Colorectal cancer - is there an alternative to 5-FU? Eur. J. Cancer (1997) 33:536–541.
   Web of Science ®Google Scholar
• AUGUST DA, OTTOW RT, SUGARBAKER PH: Clinical per-spective of human colorectal cancer metastases. Can-cer Metastases Rev. (1984) 3:303–324.
   PubMed Web of Science ®Google Scholar
• ADVANCED COLORECTAL CANCER META-ANALYSISPROJECT: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J. Clin. Oncol. (1992) 10:896–903.
   PubMed Web of Science ®Google Scholar
• ADVANCED COLORECTAL CANCER META-ANALYSIS PROJECT Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. J. Clin. Oncol. (1994) 12:960–969.
   Web of Science ®Google Scholar
• ALLEN-MERSH TG, EARLAN S, FORDY C, ABRAMS K, HOUGHTON J: Quality of life and survival with con-tinuous hepatic-artery floxiuridine infusion for colo-rectal liver metastases. Lancet (1994) 344:1255–1260.
   PubMed Web of Science ®Google Scholar
• NORDIC GASTROINTESTINAL TUMOUR ADJUVANT THERAPY GROUP: Expectancy or primary chemother-apy in patients with advanced asymptomatic colorec-tal cancer. J. Clin. Oncol. (1992) 10:904–911.
   PubMed Web of Science ®Google Scholar
• SCHEITHAUER W, ROSEN H, KORNEK GV, SEBESTA C,DEPISCH D: Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal can-cer. Br. Med. J. (1993) 306:752–755.
   PubMed Web of Science ®Google Scholar
• MOERTEL CG: Chemotherapy for colorectal cancer. New Engl. J. Med. (1994) 330:1136–1141.
   PubMed Web of Science ®Google Scholar
• PETRELLI N, HERRERA L, RUSTUM Y et al: A prospective randomized clinical trial of 5-fluorouracil versus 5-fluorouracil and high dose leucovorin versus fluorou-racil and methotrexate in previously untreated pa-tients with advanced colorectal cancer. J. Clin. Oncol (1987) 5:1559–1565.
   PubMed Web of Science ®Google Scholar
• PETRELLI N, DOUGLAS HO, Jr., HERRERA L et al: The modulation of fluorouracil with leucovorin in meta-static colorectal carcinoma: a prospective randomized Phase III trial. J. Clin. Oncol. (1989) 7:1419–1426.
   Google Scholar
• VAN CUTSEM E: A glimpse of the future. New directions in the treatment of colorectal cancer. Eur. J. Cancer (1996) 32A\(Suppl. 5):523–S27.
   Google Scholar
• JACKMAN AL, JUDSON IR: The new generation of thymidylate synthase inhibitors in clinical study. Exp. Opin. Invest. Drugs (1996) 5:719–736.
   Google Scholar
• RUSTUM YM, HARSTRICK A, CAO S et al.: Thymidylate synthase inhibitors in cancer therapy: direct and indi-rect inhibitors. J. Clin. Oncol. (1997) 15:389–400.
   PubMed Web of Science ®Google Scholar
• TOUROUTOGLOU N, PAZDUR R: Thymidylate synthase inhibitors. Clin. Cancer Res. (1996) 2:227–243.
   PubMed Web of Science ®Google Scholar
• JACKMAN AL, JONES TR, CALVERT AH: Thymidylate syn-thase inhibitors: experimental and clinical aspects. In: Experimental and Clinical Progress in Cancer Chemother-apy. Muggia FM (Ed.), Martinus Nijhoff, Boston, USA (1985):155–210.
   Google Scholar
• DANENBERG PV, DANENBERG KD: Effect of 5,10-methylenetetrahydrofolate on the dissociation of 5-fluoro-2'-deoxyuridylate from thymidylate syn-thetase: evidence for an ordered mechanism. Biochem-istry (1978) 17:4018.
   PubMed Web of Science ®Google Scholar
• RADPARVAR S, HOUGHTON PJ, HOUGHTON JA: Effect of polyglutamylation of 5,10-methylenetetrahydrofolate on the binding of 5-fluoro-2 --deoxyuridylate to thymidylate synthase purified from a human colon adenocarcinoma xenograft. Biochem. Pharmacol (1989) 38:335–342.
   PubMed Web of Science ®Google Scholar
• GREM JL: 5-Fluoropyrimidines. In: Cancer Chemotherapy, and Biotherapy: Principles and Practice (2n1 Edition). Chabner BA, Longo DL (Eds.), Lippincott-Raven, Philadel-phia, USA (1996) :149.
   Google Scholar
• CALVERT AH, JONES TR, JACKMAN AL, BROWNS SJ, HAR-RAP KR: An approach to the design of antimetabolites active against cells resistant to conventional agents il-lustrated by quinazoline antifolates with Nth-substit-utions. In: Advances in Tumour Prevention, Detection and Characterization. Davis W, Harrap KR (Eds.), Excerpta Me-dica, Amsterdam and Oxford (1980) 5:272–283.
   Google Scholar
• JONES TR, CALVERT AH, JACKMAN AH et al.: A potent an-titumour quinazoline inhibitor of thymidylate syn-thetas e: synthesis, biological properties and therapeutic results in mice. Eur. J. Cancer (1981) 17:11–19.
   PubMed Web of Science ®Google Scholar
• CALVERT AH, ALISON DL, HARLAND SJ et al.: A Phase I evaluation of the quinazoline antifolate thymidylate synthase inhibitor, N10-proparygy1-5,8-dideazafolic acid, CB3717. j Clin. Oncol. (1986) 4:1245–1252.
   PubMed Web of Science ®Google Scholar
• CLARKE SJ, JACKMAN AL, JUDSON IR: The history of the development and clinical use of CB3717 and ICI D1694. In: Proceedings of the International Symposium on Novel Approaches to Selective Treatments of Human Solid Tumours: Laboratory and Clinical Correlation. Rustum Y (Ed.), Plenum Press, New York, USA. Adv. Exp. Med. Biol. (1993) 339:277–287.
   Google Scholar
• JACKMAN AL, CALVERT AH: Folate-based thymidylate synthase inhibitors as anticancer drugs. Ann. Oncol. (1995) 6:871–881.
   PubMed Web of Science ®Google Scholar
• ALISON DL, NEWELL DR, SESSA C et al.: The clinical phar-macokinetics of the novel antifolate N10-propary1-5,8-dideazafolic acid (CB3717). Cancer Chem other. Pharma-col. (1985) 14:265–271.
   PubMed Web of Science ®Google Scholar
• CALVERT AH, NEWELL DR, JACKMAN AL et al.: Recentpreclinical and clinical studies with the thymidylate synthase inhibitor N10-propargy1-5,8-dideazafolic acid (CB3717). NCI Monograph (1987) 5:214–218.
   Google Scholar
• NEWELL DR, ALISON DL, CALVERT AH, HARRAP KR et al.:Pharmacokinetics of the thymidylate synthase inhibi-tor, N10-propargy1-5,8-dideazafolic acid (CB3717) in the mouse. Cancer Treat. Rep. (1986) 70:971–979.
   PubMedGoogle Scholar
• JACKMAN AL, FARRUGIA DC, GIBSON W et aL: ZD1694(Tomudex): a new thymidylate synthase inhibitor with activity in colorectal cancer. Eur. J. Cancer (1995) 31A:1277–1285.
   PubMed Web of Science ®Google Scholar
• JACKMAN AL, TAYLOR GA, BISHOP JA et al.: Biochemicalaspects of a new thymidylate synthase inhibitor, D1694. Proc. Am. Assoc. Cancer Res. (1990) 31:342.
   Google Scholar
• JACKMAN AL, JODRELL DI, GIBSON W, STEPHENS TC: ICID1694, an inhibitor of thymidylate synthase for clini-cal study. In: Purine and Pyrimidine Metabolism in Man. Elion GB, Zollner (Eds.), Plenum Press, New York, USA (1991) 7:19–23.
   Google Scholar
• JACKMAN AL, MARSHAM PR, MORAN RG et al.: Thymidyl-ate synthase inhibitors: the in vitro activity of a series of heterogclic benzoyl ring modified 2-desamino-2-methyl-N1 -substituted-5,8-dideazafolates. Adv. En-zyme Regul (1991) 31:13–27.
   PubMedGoogle Scholar
• JACKMAN AL, TAYLOR GA, GIBSON W et al: ICI D1694, a quinazoline antifolate thymidylate inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study. Cancer Res. (1991) 51:5579–5586.
   PubMed Web of Science ®Google Scholar
• JACKMAN AL, GIBSON W, BROWN M, KIMBELL R, BOYLE FT: The role of the reduced-folate carrier and metabo-lism to intracellular polyglutamates for the activity of ICI D1694. In: Proceedings of the International Symposium on Novel Approaches to Selective Treatments of Human Solid Tumours: Laboratory and Clinical Correlation. Rustum Y (Ed.), Plenum Press, New York, USA. Adv. Exp. Med. Biol. (1993) 339:265–276.
   Google Scholar
• WARD WHJ, KIMBELL R, JACKMAN AL: Kinetic character-istics of ICI D1694: quinazoline antifolate which inhib-its thymidylate synthase. Biochem. Pharmacol. (1992) 43:2029–2031.
   PubMed Web of Science ®Google Scholar
• SANGHANI PC, JACKMAN AL, EVANS VR et al.: A strategyfor the design of membrane-permeable folylpolygluta-mate synthetase inhibitors: 'bay region'-substituted 2-desamino-2-methy1-5,8-dideazafolate analogues. Mol. Pharmacol. (1994) 45:341–351.
   PubMed Web of Science ®Google Scholar
• AHERNE GW, FARRUGIA DC, WARD E, SUTCLIFFE F, JACKMAN AL: ZD1694 (Tomudex) and polyglutamate levels in mouse plasma and tissues measured by radio-immunoassay (RIA) and the effect of leucovorin (LV). Proc. Am. Cancer Res. (1995) 36:376.
   Google Scholar
• JACKMAN AL, GIBSON W: Polyglutamation of the thymidylate synthase inhibitor, ZD1694 (Tomudex), in normal mouse tissues. Proc. Am. Assoc. Cancer Res. (1995) 36:377.
   Google Scholar
• KIMBELL R, JACKMAN AL, BOYLE FET et al.:The duration of the inhibition of thymidylate synthase in intact L1210 cells exposed to different classes of quinazoline analogues. In: Chemistry, and Biology of Pteridines, and Fo-lates. Advances in Experimental Medicines and Biology. Ay-ling JE, Nair MG, Baugh CM (Eds.), Plenum Press, New York, USA (1993) 338:597–600.
   Google Scholar
• JODRELL DI, NEWELL DR, GIBSON W, HUGHES LR, CAL-VERT AH: The pharmacokinetics of the quinazoline an-tifolate ICI 1694 in mice and rats. Cancer Chemother. Pharmacol. (1991) 28:331–338.
   PubMed Web of Science ®Google Scholar
• JODRELL DI, NEWELL DR, CALVETE JA, STEPHENS TC, CALVERT AH: Pharmacokinetic and toxicity studies with the novel quinazoline thymidylate synthase ('TS) inhibitor, D1694. Proc. Am. Assoc. Cancer Res. (1991) 31 :341.
   Google Scholar
• CLARKE SJ, HANWELL J, DE BOER M et al.: Phase I trial ofZD1694, a new folate-based thymidylate synthase in-hibitor, in patients with solid tumors. J. Clin. Oncol (1996) 14:1495–1503.
   Google Scholar
• JUDSON IR, AHERNE GW, MAUGHAN T et al.: Pharma-cokinetic studies with Tomudex (ZD 1694). Ann. Once]. (1996) 7\(Suppl. 0:88. Abstract 304.
   Google Scholar
• JUDSON IR: `Tomudex' (raltitrexed) development - pre-clinical, Phase land II studies. Anticancer Drugs (1997) 8\(Suppl. 2):S5–S9.
   Google Scholar
• SORENSEN JM, JORDON E, GREM JL et al:Phase I trial of ZD1694 (Tomudex), a direct inhibitor of thymidylate synthase. Ann. Once]. (1994) 5 (Suppl. 5):132.
   Google Scholar
• ZALCBERG JR, CUNNINGHAM D, VAN CUTSEM E et al.: ZD1694: a novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer. J. Clin. Once]. (1996) 14:716–721.
   Google Scholar
• KERR DJ: Clinical efficacy of `Tomudex' (raltitrexed) in advanced colorectal cancer. Anticancer Drugs (1997) 8\(Suppl. 2):S11–S15.
   Google Scholar
• CUNNINGHAM D, ZALCBERG J, SMITH I et al: 'Tomudex' (ZD1694): a novel thymidylate synthase inhibitor with clinical antitumour activity in a range of solid tu-mours. Ann. Once]. (19960 7:179–182.
   Google Scholar
• VAN CUTSEM E: Future developments with `Tomudex' (raltitrexed). Anticancer Drugs (1997) 8\(Suppl. 2):S33–S38.
   Google Scholar
• ZALCBERG J: Overview of the tolerability of `Tomudex' (raltitrexed) - collective clinical experience in ad-vanced colorectal carcinoma. Anticancer Drugs (1997) 8\(Suppl. 2):S17–522.
   Google Scholar
• CUNNINGHAM D, ZALCBERG JR, RATH U et al. AND THE 'TOMUDEX' COLORECTAL CANCER STUDY GROUP: `Tomudex' (ZD1694): results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. Eur. J. Cancer (1995) 31A:1945–1954.
   PubMed Web of Science ®Google Scholar
• CUNNINGHAM D, ZALCBERG JR, RATH U et al.: Final re-sults of a randomised trial comparing Tomudex® (ral-titrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. Ann. Once]. (1996) 7:961–965.
   PubMed Web of Science ®Google Scholar
• KERR DJ, O'CONNOR K: The costs of managing ad-vanced colorectal cancer - a broad perspective. Anti-cancer Drugs (1997) 8\(Suppl. 2):S23-S26. Eric Van Cutsem, M.D., Ph.D.
   Google Scholar